StockData
Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc. (TARA) company profile

TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$2.32−0.06 (-2.52%)

Close on Nov 17, 2026Market cap $137.10MP/E –Yield –

About Protara Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its pipeline includes TARA-002, an investigational cell therapy being developed for non-muscle invasive bladder cancer and lymphatic malformations. The company is also developing intravenous choline chloride, a phospholipid substrate replacement therapy intended for adolescent and adult patients dependent on parenteral support when oral or enteral nutrition is not possible, insufficient, or contraindicated. Its intended customer base comprises patients with these oncologic and rare disease conditions who have limited treatment options.

The company operates primarily in the United States and has clinical trials and studies spanning the United States, the United Kingdom, and Europe. It holds worldwide development and commercialization rights to TARA-002, excluding Japan and Taiwan. Protara Therapeutics maintains its corporate headquarters at 345 Park Avenue South in New York, New York.

Summary of the business section of Protara Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Protara Therapeutics, Inc.
Founded
2001
Headquarters
New York, NY
Address
345 Park Avenue South, 3rd Floor 10010
Phone
(646) 844-0337
Employees
51, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, New York

Stock & identifiers

Ticker
TARA
Former tickers
PRTO until Mar 20, 2020
Exchange
Nasdaq
IPO date
Oct 22, 2014
Shares outstanding
59M, Aug 7, 2026
Public float
$112.30M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-40 reverse, Jan 10, 2020
SEC CIK
1359931
CUSIP
74365U107
ISIN
US74365U1079
FIGI
BBG001ZLYSH5
Share class FIGI
BBG001ZLYSK1
LEI
549300VWUGH3220TG273
EIN
20-4580525

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jesse SheffermanCEO and President, Director1,007,832
William ConklingChief Commercial Officer69,992
Jacqueline ZummoChief R&D Officer94,827
Hannah FryVP, Controller42,723
Patrick FabbioChief Financial Officer64,115
Leonardo Viana NicacioChief Medical Officer78,181
Cynthia SmithDirector–
Michael Edward SolomonDirector26,500
Gregory SargenDirector31,000
Roger GarceauDirector33,000
Jane HuangDirector–
Luke M. BesharDirector198,000
Barry P. FlannellyDirector–
Richard S. LevyDirector51,000

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.66M$2.31M$1.38M$199–
FY2024$1.79M$4.39M$1.11M$197–
FY2023$1.91M$1.27M$1.24M$70–
FY2022$2.78M$1.01M$1.29M$11–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Jesse Shefferman
President, Chief Executive Officer and Director
$654.89K–$294.45K$1.28M$351.18K$78.04K$2.66M+48%
Leonardo Nicacio, M.D.
Chief Medical Officer
$373.86K$75.00K$208.50K$453.44K$229.75K$41.93K$1.38M–
Jacqueline Zummo, Ph.D.
Chief R&D Officer (6)
$494.00K–$110.99K$481.84K$219.52K$75.92K$1.38M+14%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 22, 2014
Offer price
$10.00
Securities offered
6,110,000
Gross proceeds
$61.10M
Exchange
Nasdaq
First trading day
Oct 22, 2014
First-day close
$10.03+0.3%
Lock-up ends (est.)
Apr 20, 2015

“Per Share Total Initial public offering price $ 10.00 $ 61,100,000 Underwriting discount and commissions(1) $ 0.70 $ 4,277,000 Proceeds, before expenses, to us $ 9.30 $ 56,823,000 (1) We have agreed to reimburse the underwriters for certain expenses.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“we had 51 employees, 46 of whom were full-time employees and five of whom were temporary employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Mar 17, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 23, 2020Name changeName changed from ArTara Therapeutics, Inc. to Protara Therapeutics, Inc.
Mar 23, 2020Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 10, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 31, 2019Name changeName changed from PROTEON THERAPEUTICS INC to ArTara Therapeutics, Inc.
Nov 7, 2019MergerRegistration of securities for a merger or exchange offer (S-4)
Oct 10, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 15, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 15, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 22, 2014IPOInitial public offering priced (424B4 prospectus)
Oct 16, 2014ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?